Graduate School of Heilongjiang University of Chinese Medicine, Harbin, 150040, Heilongjiang, China.
School of Pharmacy, Lebanese International University, 18644, Sana'a, Yemen.
Sci Rep. 2023 Jul 6;13(1):10944. doi: 10.1038/s41598-023-38020-0.
Hypertension is the most prevalent chronic disease World-wide, and the leading preventable risk factor for cardiovascular disease (CVD). Few patients accomplish the objective of decreasing blood pressure and avoiding hypertensive target organ damage after treatments with antihypertensive agents which opens the door for other treatments, such as herbal-and antihypertensive combination therapy. Captopril (CAP), as a-pril which inhibits angiotensin converting enzyme has long been used in the management of hypertension and CVD. Gedan Jiangya Decoction (GJD) is known for antihypertensive effects in prior studies. The research is aimed to determine whether GJD in combination with captopril has antihypertensive, kidney protective, antioxidant, and vasoactive effects in spontaneously hypertensive rats (SHR). Regular measurements of systolic and diastolic blood pressure (SBP and DBP), and body weight were monitored weekly. H&E staining was utilized to examine histopathology. The combined effects were studied using ELISA, immunohistochemistry, and qRT-PCR. Significant reductions in SBP, DBP, aortic wall thickness, and improvement in renal tissue were observed following GJD + CAP treatment, with increased serum levels of NO, SOD, GSH-Px, and CAT and decreases in Ang II, ET-1, and MDA. Similarly, GJD + CAP treatment of SHR's significantly decreased ET-1 and AGTR1 mRNA and protein expression while increasing eNOS mRNA and protein expression in thoracic aorta and kidney tissue. In conclusion, the present investigation found that GJD + CAP treatment decreases SHR blood pressure, improves aorta remodeling and renal protection, and that this effect could be attributable, in part, due to antioxidant and vascular tone improvement.
高血压是全球最普遍的慢性疾病，也是心血管疾病（CVD）的主要可预防风险因素。在使用抗高血压药物治疗后，很少有患者能够达到降低血压和避免高血压靶器官损伤的目标，这为其他治疗方法（如草药和抗高血压联合治疗）提供了机会。卡托普利（CAP）是一种抑制血管紧张素转换酶的-pril，长期以来一直用于高血压和 CVD 的治疗。在之前的研究中，葛根降压汤（GJD）已被证明具有降压作用。本研究旨在确定 GJD 与卡托普利联合使用是否对自发性高血压大鼠（SHR）具有降压、肾保护、抗氧化和血管活性作用。每周定期测量收缩压和舒张压（SBP 和 DBP）和体重。使用 H&E 染色检查组织病理学。使用 ELISA、免疫组化和 qRT-PCR 研究联合作用。结果表明，GJD+CAP 治疗后 SBP、DBP、主动脉壁厚度显著降低，肾组织改善，血清中 NO、SOD、GSH-Px 和 CAT 水平升高，Ang II、ET-1 和 MDA 水平降低。同样，GJD+CAP 治疗 SHR 的 ET-1 和 AGTR1 mRNA 和蛋白表达显著降低，而胸主动脉和肾组织中 eNOS mRNA 和蛋白表达增加。总之，本研究发现 GJD+CAP 治疗可降低 SHR 的血压，改善主动脉重塑和肾脏保护，这种作用部分归因于抗氧化和血管张力的改善。
